Literature DB >> 20038640

Defective ribosomal products are the major source of antigenic peptides endogenously generated from influenza A virus neuraminidase.

Brian P Dolan1, Lily Li, Kazuyo Takeda, Jack R Bennink, Jonathan W Yewdell.   

Abstract

The defective ribosomal product (DRiP) hypothesis of endogenous Ag processing posits that rapidly degraded forms of nascent proteins are a major source of peptide ligands for MHC class I molecules. Although there is broad experimental support for the DRiP hypothesis, careful kinetic analysis of the generation of defined peptide class I complexes has been limited to studies of recombinant vaccinia viruses expressing genes derived from other organisms. In this study, we show that insertion of the SIINFEKL peptide into the stalk of influenza A virus neuraminidase (NA) does not detectably modify NA folding, degradation, transport, or sp. act. when expressed in its natural context of influenza A virus infection. Using the 25-D1.16 mAb specific for K(b)-SIINFEKL to precisely quantitate cell surface complexes by flow cytometry, we demonstrate that SIINFEKL is generated in complete lockstep with initiation and abrogation of NA biosynthesis in both L-K(b) fibroblast cells and DC2.4 dendritic/monocyte cells. SIINFEKL presentation requires active proteasomes and TAP, consistent with its generation from a cytosolic DRiP pool. From the difference in the shutoff kinetics of K(b)-SIINFEKL complex expression following protein synthesis versus proteasome inhibition, we estimate that the t(1/2) of the biosynthetic source of NA peptide is approximately 5 min. These observations extend the relevance of the DRiP hypothesis to viral proteins generated in their natural context.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20038640      PMCID: PMC2940057          DOI: 10.4049/jimmunol.0901907

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes.

Authors:  U Schubert; L C Antón; J Gibbs; C C Norbury; J W Yewdell; J R Bennink
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

2.  Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein.

Authors:  S Khan; R de Giuli; G Schmidtke; M Bruns; M Buchmeier; M van den Broek; M Groettrup
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

3.  Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I.

Authors:  Eric Reits; Alexander Griekspoor; Joost Neijssen; Tom Groothuis; Kees Jalink; Peter van Veelen; Hans Janssen; Jero Calafat; Jan Wouter Drijfhout; Jacques Neefjes
Journal:  Immunity       Date:  2003-01       Impact factor: 31.745

4.  Quantitating protein synthesis, degradation, and endogenous antigen processing.

Authors:  Michael F Princiotta; Diana Finzi; Shu-Bing Qian; James Gibbs; Sebastian Schuchmann; Frank Buttgereit; Jack R Bennink; Jonathan W Yewdell
Journal:  Immunity       Date:  2003-03       Impact factor: 31.745

Review 5.  To DRiP or not to DRiP: generating peptide ligands for MHC class I molecules from biosynthesized proteins.

Authors:  Jonathan Yewdell
Journal:  Mol Immunol       Date:  2002-10       Impact factor: 4.407

6.  Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin.

Authors:  T van Hall; J van Bergen; P A van Veelen; M Kraakman; L C Heukamp; F Koning; C J Melief; F Ossendorp; R Offringa
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

7.  Kinetics of degradation of "short-" and "long-lived" proteins in cultured mammalian cells.

Authors:  D N Wheatley; M R Giddings; M S Inglis
Journal:  Cell Biol Int Rep       Date:  1980-12

8.  Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway.

Authors:  Claudia Neumeister; Ralph Nanan; Tatjana I Cornu; Carsten G K Lüder; Volker Ter Meulen; Hussein Naim; Stefan Niewiesk
Journal:  J Gen Virol       Date:  2001-02       Impact factor: 3.891

9.  XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation.

Authors:  A L Shaffer; Miriam Shapiro-Shelef; Neal N Iwakoshi; Ann-Hwee Lee; Shu-Bing Qian; Hong Zhao; Xin Yu; Liming Yang; Bruce K Tan; Andreas Rosenwald; Elaine M Hurt; Emmanuel Petroulakis; Nahum Sonenberg; Jonathan W Yewdell; Kathryn Calame; Laurie H Glimcher; Louis M Staudt
Journal:  Immunity       Date:  2004-07       Impact factor: 31.745

10.  Transience of MHC Class I-restricted antigen presentation after influenza A virus infection.

Authors:  Justine D Mintern; Sammy Bedoui; Gayle M Davey; Jessica M Moffat; Peter C Doherty; Stephen J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-03       Impact factor: 11.205

View more
  26 in total

Review 1.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

2.  Influenza A virus hemagglutinin trimerization completes monomer folding and antigenicity.

Authors:  Javier G Magadán; Surender Khurana; Suman R Das; Gregory M Frank; James Stevens; Hana Golding; Jack R Bennink; Jonathan W Yewdell
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

3.  RNA polymerase II inhibitors dissociate antigenic peptide generation from normal viral protein synthesis: a role for nuclear translation in defective ribosomal product synthesis?

Authors:  Brian P Dolan; Jonathan J Knowlton; Alexandre David; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2010-11-03       Impact factor: 5.422

4.  Hydrophobicity as a driver of MHC class I antigen processing.

Authors:  Lan Huang; Matthew C Kuhls; Laurence C Eisenlohr
Journal:  EMBO J       Date:  2011-03-04       Impact factor: 11.598

5.  Distinct pathways generate peptides from defective ribosomal products for CD8+ T cell immunosurveillance.

Authors:  Brian P Dolan; Lily Li; Charles A Veltri; Chris M Ireland; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2011-01-12       Impact factor: 5.422

6.  Ubiquitous Autofragmentation of Fluorescent Proteins Creates Abundant Defective Ribosomal Products (DRiPs) for Immunosurveillance.

Authors:  Jiajie Wei; James S Gibbs; Heather D Hickman; Stephanie S Cush; Jack R Bennink; Jonathan W Yewdell
Journal:  J Biol Chem       Date:  2015-05-13       Impact factor: 5.157

7.  Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance.

Authors:  Jiajie Wei; Rigel J Kishton; Matthew Angel; Crystal S Conn; Nicole Dalla-Venezia; Virginie Marcel; Anne Vincent; Frédéric Catez; Sabrina Ferré; Lilia Ayadi; Virginie Marchand; Devin Dersh; James S Gibbs; Ivaylo P Ivanov; Nathan Fridlyand; Yohann Couté; Jean-Jacques Diaz; Shu-Bing Qian; Louis M Staudt; Nicholas P Restifo; Jonathan W Yewdell
Journal:  Mol Cell       Date:  2019-01-31       Impact factor: 17.970

8.  Alternative Start Sites Downstream of Non-Sense Mutations Drive Antigen Presentation and Tolerance Induction to C-Terminal Epitopes.

Authors:  Scott N Ashley; Suryanarayan Somanathan; Christian Hinderer; Maxwell Arias; Deirdre McMenamin; Christine Draper; James M Wilson
Journal:  J Immunol       Date:  2017-05-12       Impact factor: 5.422

9.  Defining Viral Defective Ribosomal Products: Standard and Alternative Translation Initiation Events Generate a Common Peptide from Influenza A Virus M2 and M1 mRNAs.

Authors:  Ning Yang; James S Gibbs; Heather D Hickman; Glennys V Reynoso; Arun K Ghosh; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2016-03-25       Impact factor: 5.422

10.  Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome.

Authors:  Anju Bansal; Tiffanie Mann; Sarah Sterrett; Binghao J Peng; Anne Bet; Jonathan M Carlson; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2015-09-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.